Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Neuro-Oncology

• Publication date

  2017-03-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11060-017-2388-xPMID 28290002PMCID PMC7983166
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Quantification of Temozolomide in Nonhuman Primate Fluids by Isocratic Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry to Study Brain Tissue Penetration Following Intranasal or Intravenous Delivery.

  2016cited by this paper
• DIPG in Children – What Can We Learn from the Past?

  2015cited by this paper
• Plasma and cerebrospinal fluid pharmacokinetics of the Akt inhibitor, perifosine, in a non-human primate model

  2015cited by this paper
• The Blood-Brain Barrier and Nasal Drug Delivery to the Central Nervous System

  2015cited by this paper
• The nasal approach to delivering treatment for brain diseases: an anatomic, physiologic, and delivery technology overview.

  2014cited by this paper
• A systematic review of inhaled intranasal therapy for central nervous system neoplasms: an emerging therapeutic option

  2014cited by this paper
• Insights into direct nose to brain delivery: current status and future perspective

  2014cited by this paper
• Long-term outcome in patients with recurrent malignant glioma treated with Perillyl alcohol inhalation.

  2013cited by this paper
• Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?

  2013cited by this paper
• Relationship of Coping Styles with Suicidal Behavior in Hospitalized Asthma and Chronic Obstructive Pulmonary Disease Patients: Substance Abusers versus Non- Substance Abusers.

  2013cited by this paper
• Blood–brain barrier structure and function and the challenges for CNS drug delivery

  2013cited by this paper
• Novel therapeutic delivery approaches in development for pediatric gliomas.

  2013cited by this paper
• Guide for the Care and Use of Laboratory Animals (8th edn)

  2012cited by this paper
• Nasal drug delivery devices: characteristics and performance in a clinical perspective—a review

  2012cited by this paper
• Intranasal delivery of biologics to the central nervous system.

  2012cited by this paper
• Nasal drug delivery in humans.

  2011cited by this paper
• Intranasal delivery to the central nervous system: mechanisms and experimental considerations.

  2010cited by this paper
• Trigeminal pathways deliver a low molecular weight drug from the nose to the brain and orofacial structures.

  2010cited by this paper
• Intranasal fentanyl: from pharmacokinetics and bioavailability to current treatment applications

  2010cited by this paper
• Transnasal delivery of methotrexate to brain tumors in rats: a new strategy for brain tumor chemotherapy.

  2010cited by this paper
• Various drug delivery approaches to the central nervous system

  2010cited by this paper
• Intranasal drug delivery: how, why and what for?

  2009cited by this paper
• Predictability of intranasal pharmacokinetics in man using pre-clinical pharmacokinetic data with a dopamine 3 receptor agonist, PF-219061

  2009cited by this paper
• Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates

  2008cited by this paper
• Delivery of interferon-beta to the monkey nervous system following intranasal administration.

  2008cited by this paper
• New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163.

  2008cited by this paper
• Can Nasal Drug Delivery Bypass the Blood-Brain Barrier?

  2007cited by this paper
• Intranasal delivery: physicochemical and therapeutic aspects.

  2007cited by this paper
• Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates

  2007cited by this paper
• Plasma and Cerebrospinal Fluid Pharmacokinetics of Intravenous Temozolomide in Non-human Primates

  2003cited by this paper
• Transport of drugs from the nasal cavity to the central nervous system.

  2000cited by this paper
• Guide for the Care and Use of Laboratory Animals

  1996influential reference
• Comparative pathology of the nasal mucosa in laboratory animals exposed to inhaled irritants.

  1990cited by this paper

• mPEG-PLA micelles for nose-to-brain delivery of crizotinib-heptamethine cyanine dye conjugate for potential treatment of glioblastoma

  2025cites this paper
• Intranasal Drug Delivery Technology in the Treatment of Central Nervous System Diseases: Challenges, Advances, and Future Research Directions

  2025cites this paper
• Preparation, and ex vivo and in vivo Characterization of Favipiravir-Loaded Aspasomes and Niosomes for Nose-to-Brain Administration

  2025cites this paper
• Temozolomide Treatment in Refractory Pituitary Adenomas and Pituitary Carcinomas

  2025cites this paper
• Proposal for reference values for the developmental effects of valproate based on human data using a benchmark dose approach.

  2023cites this paper
• Temozolomide: an Overview of Biological Properties, Drug Delivery Nanosystems, and Analytical Methods.

  2022cites this paper
• Intranasal administration of fingolimod (FTY720) attenuates demyelination area in lysolecithin-induced demyelination model of rat optic chiasm.

  2022cites this paper
• Swine models for translational oncological research: an evolving landscape and regulatory considerations

  2021cites this paper
• Overview of Current Drug Delivery Methods Across the Blood–Brain Barrier for the Treatment of Primary Brain Tumors

  2020cites this paper
• Considering the Experimental Use of Temozolomide in Glioblastoma Research

  2020cites this paper
• Revealing the epigenetic effect of temozolomide on glioblastoma cell lines in therapeutic conditions

  2020cites this paper
• In vitro and in vivo models of BBB to evaluate brain targeting drug delivery

  2019cites this paper
• How to Make Anticancer Drugs Cross the Blood–Brain Barrier to Treat Brain Metastases

  2019cites this paper
• Blood–Brain Barrier in Disease States

  2019cites this paper
• Intersection of Brain Development and Paediatric Diffuse Midline Gliomas: Potential Role of Microenvironment in Tumour Growth

  2018cites this paper
• Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques.

  2018cites this paper